Dr. Thomas Serena Joins NATROX® Wound Care Team as Chief Medical Officer
Acclaimed wound care expert adds increased clinical credibility and strategic knowledge of US reimbursement
[4 May 2022 – Cambridge, UK] – NATROX® Wound Care is excited to announce the addition of Dr. Thomas Serena, MD FACS FACHM MAPWCA, who joins as Chief Medical Officer (CMO) effective immediately. The internationally recognised expert in the field of wound healing has been the lead or Principal Investigator in over 100 clinical trials. He has a vast knowledge of oxygen therapy and understands its positive impact on chronic wounds.
Dr. Serena will support the team to make its flagship product, NATROX® Oxygen Wound Therapy, available globally to patients with chronic wounds. Designed simply to heal wounds, NATROX® O₂ generates oxygen to stimulate healing in previously non-healing wounds. Due to its small size, the device is easy to carry. Patients receive treatment 24/7, leading to better healing outcomes. Recent studies indicate NATROX® O₂ is poised to become the new standard in wound care, giving hope to patients suffering from long-standing wounds¹.
“Having Tom onboard adds tremendous clinical credibility around the wound care benefits of topical oxygen,” said Craig Kennedy, CEO. “Tom will be supporting our strategy to making NATROX® O₂ readily available to all patients, which includes securing USA reimbursement.”
Founder and Medical Director of The SerenaGroup®, a group of wound care clinics, Dr. Serena is a vascular surgeon and long-time proponent of hyperbaric oxygen therapy. Joining forces with NATROX® Wound Care illustrates the inherent synergy between the two companies.
“I’m thrilled to join the NATROX® family and serve as a strong advocate for topical oxygen therapy,” said Dr. Serena. “It’s time for the market to accept what clinicians already know – that topical oxygen has a key role to play in the wound care specialists’ armamentarium. The simplicity of NATROX® O2 distinguishes it from other forms of oxygen therapy. I’ve witnessed first-hand how it excels in treating a wide variety of wound types.”
Because topical oxygen therapy is so portable, treatment can occur across a wide variety of care settings. Dr. Serena explained how the recent COVID-19 pandemic showed the immense value in having the option to treat patients remotely.
Dr. Serena has published more than 200 papers and given more than 1,000 lectures worldwide. His well-decorated tenure includes past-President of the Association for the Advancement of Wound Care (AAWC) and the American Professional Wound Care Association, former board member of the Wound Healing Society, and also Vice-President of the American College of Hyperbaric Medicine. He has also developed a diagnostic technique to collect proteases from chronic wounds, called The Serena Technique©2.
Dr. Serena will work from his office in Pittsburgh, Pennsylvania while continuing his medical practice.
- Serena TE, Bullock NM, Cole W et al. Topical oxygen therapy in the treatment of diabetic foot ulcers: a multicentre, open, randomised controlled trial. J Wound Care 2021; 30: Suppl.5 S7-14.
- Serena TE. Development of a Novel Technique to Collect Proteases from Chronic Wounds. Adv Wound Care (New Rochelle). 2014;3(12):729-732. doi:10.1089/wound.2013.0463
# # #
About Inotec AMD Ltd.
NATROX® Wound Care is an Inotec AMD brand. The specialist wound care company based in Cambridge, England was formed specifically to introduce new technologies to healthcare professionals around the world to promote faster and better healing to patients. The company’s flagship product, NATROX® Oxygen Wound Therapy, is positioned to become an integral part of global wound care treatment regimes in the coming years. To learn more, visit: natroxwoundcare.com.